Cardiovascular disease in patients with renal disease: the role of statins

References

• Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008;8:117
   PubMed Web of Science ®Google Scholar
• Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47
   PubMed Web of Science ®Google Scholar
• Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;17 (Suppl 11):8-12
   PubMed Web of Science ®Google Scholar
• U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006
   Google Scholar
• Xue JL, Ma JZ, Louis TA, et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001;12:2753-8
   PubMed Web of Science ®Google Scholar
• Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13 (Suppl 1):S37-40
   PubMed Web of Science ®Google Scholar
• Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-47
   PubMed Web of Science ®Google Scholar
• Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001;16:1545-9
   PubMed Web of Science ®Google Scholar
• Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Haemodial Int 2007;11:1-14
   PubMedGoogle Scholar
• Tomilina NA, Storozhakov GI, Gendlin GE, et al. Risk factors and pathogenetic mechanisms of left ventricular hypertrophy in progressive chronic kidney disease and after transplantation of the kidney. Ter Arkh 2007;79:34-40
   PubMed Web of Science ®Google Scholar
• Molitch ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1090-9
   PubMed Web of Science ®Google Scholar
• Goodman WG. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? Curr Opin Nephrol Hypertens 2005;14:355-60
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17
   PubMed Web of Science ®Google Scholar
• Fabbian F, Catalano C, Orlandi V, et al. Evaluation of aortic arch calcification in hemodialysis patients. J Nephrol 2005;18:289-93
   PubMed Web of Science ®Google Scholar
• Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41 (Suppl 5):S11-17
   PubMed Web of Science ®Google Scholar
• Braun J, Asmus HG, Holzer Hospital, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate–phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-15
   PubMed Web of Science ®Google Scholar
• Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96
   PubMed Web of Science ®Google Scholar
• Annuk M, Soveri I, Zilmer M, et al. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 2005;18:721-6
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41
   PubMed Web of Science ®Google Scholar
• Attman PO, Alaupovic P, Tavella M, et al. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 1996;11:63-9
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Lakatua JD, Ma JZ, et al. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998;31:954-61
   PubMed Web of Science ®Google Scholar
• Deighan CJ, Caslake MJ, McConnell M, et al. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000;35:852-62
   PubMed Web of Science ®Google Scholar
• Attman PO, Knight-Gibson C, Tavella M, et al. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 1998;13:2833-41
   PubMed Web of Science ®Google Scholar
• Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004;140:9-17
   PubMed Web of Science ®Google Scholar
• Kimak E, Solski J. ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Ren Fail 2002;24:485-92
   PubMed Web of Science ®Google Scholar
• Karie S, Launay-Vacher V, Deray G, et al. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant.] Presse Med 2006;35:219-29
   PubMed Web of Science ®Google Scholar
• Tonelli M. The effect of statins on preservation of kidney function in patients with coronary artery disease. Curr Opin Cardiol 2006;21:608-12
   PubMed Web of Science ®Google Scholar
• Chan DT, Irish AB, Dogra GK, et al. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 2008;196:823-34
   PubMed Web of Science ®Google Scholar
• Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003;14 (Suppl 4):S31-20
   Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41 (Suppl 3):S1-91
   PubMed Web of Science ®Google Scholar
• Attman PO, Samuelsson OG, Moberly J, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536-42
   PubMed Web of Science ®Google Scholar
• Moberly JB, Attman PO, Samuelsson O, et al. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 2002;22:220-8
   PubMed Web of Science ®Google Scholar
• Llopart R, Doñate T, Oliva JA, et al. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant 1995;10:537-40
   PubMed Web of Science ®Google Scholar
• Kronenberg F, König P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-20
   PubMed Web of Science ®Google Scholar
• Iseki K, Yamazato M, Tozawa M, et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887-93
   PubMed Web of Science ®Google Scholar
• Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4 (Suppl 7):13-53
   PubMed Web of Science ®Google Scholar
• Shoji T, Nishizawa Y, Kawagishi T, et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998;9:1277-84
   PubMed Web of Science ®Google Scholar
• Dumler F, Kilates C. Metabolic and nutritional complications of renal transplantation. J Ren Nutr 2007;17:97-102
   PubMed Web of Science ®Google Scholar
• Pannu HS, Singh D, Sandhu JS. Lipid profile before and after renal transplantation – a longitudinal study. Ren Fail 2003;25:411-17
   PubMed Web of Science ®Google Scholar
• Kimak E, Solski J, Baranowicz-Gaszczyk I, et al. A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. Ren Fail 2006;28:483-6
   PubMed Web of Science ®Google Scholar
• Jardine AG, Fellström B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005;46:529-36
   PubMed Web of Science ®Google Scholar
• Coresh J, Longenecker JC, Miller ER III, et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998;9 (Suppl 12):S24-30
   PubMedGoogle Scholar
• Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-9
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51
   PubMed Web of Science ®Google Scholar
• Farwell D, Gollob MH. Risk stratification for sudden death in heart failure. Minerva Cardioangiol 2007;55:379-84
   PubMedGoogle Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   Google Scholar
• Wanner C, Krane V, Marz W, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellström B, Jardine AG, et al.; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31
   Google Scholar
• Kaisar MO, Isbel NM, Johnson DW. Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Rev Recent Clin Trials 2008;3:79-88
   PubMedGoogle Scholar
• Herzog CA. Don't forget the defibrillator in the dialysis unit. Nephrol Dial Transplant 2004;19:2959-60
   PubMed Web of Science ®Google Scholar
• McCullough PA. Cardiovascular care in end-stage renal disease. Adv Chronic Kidney Dis 2004;11:245
   PubMed Web of Science ®Google Scholar
• Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 2002;80:35-8
   PubMedGoogle Scholar
• Zamboli P, De Nicola L, Minutolo R, et al. Heart failure in chronic kidney disease: from epidemiology to therapy. G Ital Nefrol 2007;24:574-83
   PubMedGoogle Scholar
• Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005;67:217-26
   PubMed Web of Science ®Google Scholar
• Haydar AA, Covic A, Colhoun H, et al. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004;65:1790-4
   PubMed Web of Science ®Google Scholar
• Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297-304
   PubMed Web of Science ®Google Scholar
• Asselbergs FW, Diercks GF, Hillege HL, et al.; Prevention of renal and vascular endstage disease intervention trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-16
   PubMed Web of Science ®Google Scholar
• Steinmetz OM, Panzer U, Stahl RA, et al. Statin therapy in patients with chronic kidney disease: to use or not to use. Eur J Clin Invest 2006;36:519-27
   PubMed Web of Science ®Google Scholar
• Dogra G, Irish A, Chan D, et al. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007;49:776-85
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, et al.; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-58
   PubMed Web of Science ®Google Scholar
• Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-63
   PubMed Web of Science ®Google Scholar
• Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16
   PubMed Web of Science ®Google Scholar
• Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260-9
   PubMed Web of Science ®Google Scholar
• Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006;97:1602-6
   PubMed Web of Science ®Google Scholar
• Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70
   PubMed Web of Science ®Google Scholar
• van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2152-7
   PubMed Web of Science ®Google Scholar
• Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980-7
   PubMed Web of Science ®Google Scholar
• Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002;40:67-73
   PubMed Web of Science ®Google Scholar
• Tonelli M, Moyé L, Sacks FM, et al.; Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14:1605-13
   Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
   Google Scholar
• Kano K, Nishikura K, Yamada Y, et al. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol 2003;60:85-9
   PubMed Web of Science ®Google Scholar
• Kano K, Nishikura K, Yamada Y, et al. No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clin Nephrol 2005;63:74-9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V, et al.; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9
   PubMed Web of Science ®Google Scholar
• Rahman M, Baimbridge C, Davis BR, et al.; ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008; 52:412-24
   PubMed Web of Science ®Google Scholar
• Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006;145:117-24
   PubMed Web of Science ®Google Scholar
• Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112:171-8
   PubMed Web of Science ®Google Scholar
• Kshirsagar AV, Shoham DA, Bang H, et al. The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis 2005;46:812-9
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Gazi I, et al. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol 2006;46:1337-43
   PubMed Web of Science ®Google Scholar
• Zipes DP, Zvaifler NJ, Glassock RJ, et al. Rosuvastatin: an independent analysis of risks and benefits. Med Gen Med 2006;8:73
   PubMedGoogle Scholar
• Kasiske BL, Wanner C, O’Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006;97 (Suppl 8A):82C-85C
   PubMed Web of Science ®Google Scholar
• Akdim F, van Leuven SI, Kastelein JJ, . et al. ESPleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque? Curr Pharm Des 2007;13:1003-12
   PubMed Web of Science ®Google Scholar
• John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation 1998;98:211-6
   PubMed Web of Science ®Google Scholar
• Ott C, Schlaich MP, Schmidt BM, et al. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008;196:704-11
   PubMed Web of Science ®Google Scholar
• Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007;9:622-8
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Clearfield M, et al.; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65
   PubMed Web of Science ®Google Scholar
• Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003-9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Shepherd J, Bittner V, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54
   PubMed Web of Science ®Google Scholar
• Shepherd J, Shepherd J, Bittner VA, et al.; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008;83:870-9
   PubMedGoogle Scholar
• Shepherd J, Moyé L, Sacks FM, et al.; Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138:98-104
   PubMedGoogle Scholar
• Shepherd J, Shepherd J, Parish S, et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Lins RL, Matthys KE, Billiouw JM, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004;62:287-94
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Shrivastava R. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2004;4:CD004289
   Google Scholar
• Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005;45:119-26
   PubMed Web of Science ®Google Scholar
• Shepherd J, Fellström B, Jardine AG, et al.; ALERT Study Group. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 2005;20:974-80
   Google Scholar
• Shepherd J, Fellström B, Cole E, et al.; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005;5:2929-36
   PubMedGoogle Scholar
• Holdaas H, Wanner C, Abletshauser C, et al. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 2007;117:64-74
   PubMed Web of Science ®Google Scholar
• Chonchol M, Cook T, Kjekshus J, et al. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 2007;49:373-82
   PubMed Web of Science ®Google Scholar
• Shepherd J, Shepherd J, Jørgensen KA, et al.; OPACH Study Group. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006;1:780-6
   PubMed Web of Science ®Google Scholar
• Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007;82:1381-94
   PubMed Web of Science ®Google Scholar
• Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;84:S207-10
   PubMed Web of Science ®Google Scholar
• Fellström B, Shepherd J, Shepherd J, et al.; AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005;6:9
   PubMedGoogle Scholar
• Fellström B, Shepherd J, Jardine AG, et al.; AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res 2007;30:314-22
   PubMed Web of Science ®Google Scholar
• Rossebø AB, Shepherd J, Shepherd J, et al.; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-66
   PubMed Web of Science ®Google Scholar
• Fassett RG, Ball MJ, Robertson IK, et al. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol 2008;9:4
   PubMed Web of Science ®Google Scholar